As of Nov 19, 2026, 2 of 2 active firms rate GRI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
GRI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.98
Range $-0.98 – $-0.98 · 1 analysts · -39% YoY
Next period, 1 analysts expect GRI Bio Inc. to earn $-0.98 a share (range $-0.98 – $-0.98), versus $-1.61 a year earlier. Full-year consensus is $-3.90, growing to $-2.00 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering GRI Bio Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GRI.
#1
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$10.00+681.3% to target
Overall win rate
34%
+ Follow
#2
Edward Woo
Ascendiant Capital · Rank #570
Buy
$27.00+2009.4% to target
Overall win rate
24%
+ Follow
#3
MK
Matthew Keller
HC Wainwright & Co.
Buy
$10.00+681.3% to target
Coverage
—
+ Follow
#4
EW
Edward Woo
Ascendiant
Buy
$32.00+2400.0% to target
Coverage
—
+ Follow
GRI stock forecast FAQ
What is GRI's average 12-month price target?+
The 2 active firms with a live target average $18.50 for GRI Bio Inc. over the next 12 months, ranging from a $27.00 high to a $10.00 low, as of Nov 19, 2026.
Is GRI stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for GRI?+
The Street-high target is $27.00 (Ascendiant Capital), and the Street-low is $10.00 (HC Wainwright & Co.). The average of all 2 active-firm targets is $18.50.
How many active Wall Street firms cover GRI?+
2 active firms have a recognized rating on GRI Bio Inc. as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering GRI?+
Among analysts who currently cover GRI, Joseph Pantginis of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #373). Their current call is Buy with a $10.00 target.
What is GRI Bio Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.98 per share (range $-0.98 – $-0.98) across 1 analysts. Full-year EPS is projected at $-3.90, rising to $-2.00 the following year.
How much revenue is GRI Bio Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading GRI lately?+
As of Nov 19, 2026, 2 of 2 active firms rate GRI a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GRI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.